drugset / Trial / NCT04330664
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
Timeline
- Start
- 2020-04-07
- Primary completion
- 2022-07-29
- Completion
- 2025-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | — | Oral |
| Subject | BATOPROTAFIB | Small molecule | — | Oral |